Evidence map›Paper›PMID 40958409›Full record

ArticleBrain and behavior2025

Anxiety in Myasthenia Gravis Patients Throughout the COVID-19 Pandemic-Prevalence, Risk Factors, and Association With Vaccination Status.

Janna Beckmann, Moritz Petzold, Felix Betzler, Andreas Ströhle, Antonia Bendau, Carla Dusemund, Gabor C Petzold, Andreas Meisel, Sarah Hoffmann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Janna BeckmannDepartment of Vascular Neurology, University Hospital Bonn, Bonn, Germany.
Moritz PetzoldDepartment of Psychiatry and Neurosciences, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Felix BetzlerDepartment of Psychiatry and Neurosciences, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Andreas StröhleDepartment of Psychiatry and Neurosciences, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Antonia BendauDepartment of Psychiatry and Neurosciences, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.
Carla DusemundDepartment of Psychology-Medical School Berlin, Berlin, Germany.
Gabor C PetzoldDepartment of Vascular Neurology, University Hospital Bonn, Bonn, Germany.
Andreas MeiselDepartment of Neurology and NeuroCure Clinical Research Center, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Sarah HoffmannDepartment of Psychology-Medical School Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionA high prevalence of COVID-19-related anxiety was observed among the general population during the COVID-19 pandemic. Patients with myasthenia gravis (MG) might be at higher risk for COVID-19-related anxiety due to immunosuppressive therapy in the majority of cases and risk of myasthenic exacerbation in case of an infection. This prospective longitudinal study assessed COVID-19-related anxiety in MG patients over 2 years of the pandemic and its association with MG-specific factors (e.g., disease severity, immunosuppressive medication) and with vaccination status.

methodsA three-wave longitudinal online survey was conducted from May 2020 to February 2022, including a total of 648 adult MG patients. Descriptive, univariate, and multivariate analyses were performed to assess COVID-19-related and MG-related anxiety, associated MG-specific factors, and association with vaccination status.

resultsCOVID-19-related anxiety was frequent, with the most pronounced fear being risk for one's own health (overall 83.9%). Anxiety was influenced by MG diagnosis (overall 75.1%), especially by fear of exacerbation of myasthenic symptoms and greater risk of infection due to immunosuppressive therapy. Female sex and treatment with immunosuppressive medication, including rituximab, were associated with an increased concern for one's own health. Fear for one's own health was the only factor associated with vaccination status.

conclusionsCOVID-19-related anxiety was prevalent among MG patients. An ongoing psychological impact is likely and highlights the need for anxiety screening in clinical practice. Our findings emphasize the importance of addressing mental health challenges during future pandemics.

Indexed as

AnxietyCOVID-19Myasthenia GravisVaccinationAdultAgedFemaleHumansImmunosuppressive AgentsLongitudinal StudiesMaleMiddle AgedPrevalenceProspective StudiesRisk FactorsSARS-CoV-2Immunosuppressive Agentsautoimmune diseasecoronafearimmunosuppressive treatment

Identifiers

PMID40958409
PMCPMC12441002

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.